Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment

There are fewer than normal glucose transporters at the blood-brain barrier (BBB) in Alzheimer’s disease (AD). When reduced expression of transporters aggravates the symptoms of AD, the transporters become a potential target of therapy. The incretin hormone GLP-1 prevents the decline of cerebral met...

Descripción completa

Detalles Bibliográficos
Autores principales: Gejl, Michael, Brock, Birgitte, Egefjord, Lærke, Vang, Kim, Rungby, Jørgen, Gjedde, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727512/
https://www.ncbi.nlm.nih.gov/pubmed/29235507
http://dx.doi.org/10.1038/s41598-017-17718-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727512/
https://www.ncbi.nlm.nih.gov/pubmed/29235507
http://dx.doi.org/10.1038/s41598-017-17718-y

Ejemplares similares